Summarized by Masters of Longevity from Longevity Technology.
An update on clinical progress for a Parkinson’s cell therapy, previewing safety and imaging results and plans for the next trial stage.
Key Takeaways
- The Phase I trial of XS411 enrolled nine moderate-to-advanced Parkinson’s patients and met primary safety and tolerability objectives without dose-limiting toxicities.
- 18F-DOPA PET imaging showed increased tracer uptake at transplant sites, indicating cell survival, engraftment, and restored dopamine synthesis potential.
- A multicenter, randomized PROBE-designed Phase II trial has begun enrollment in China, already recruiting thirty participants.
